Treatment strategies for pelvic pain associated with adenomyosis

V E Radzinsky, M B Khamoshina, М.Б. Хамошина, О. М. Носенко, E N Nosenko, A O Dukhin, А. О. Духин, M A Sojunov, A A Orazmuradov, А.А. Оразмурадов, М. G. Lebedeva, M G Lebedeva, M R Orazov, Mekan R. Orazov
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2016 · vol. 32(sup2) , pp. 19–22 · doi:10.1080/09513590.2016.1232673 · PMID:27759444 · W2536998678
article OA: hybrid CC0 ⤵ 16 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Levonorgestrel-releasing intrauterine system insertion significantly reduced chronic pelvic pain scores in women with adenomyosis, with no universal predictors of pain improvement.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-05, 2026-05-18 ⓘ

This study tracked 180 reproductive-age women (31–46) with chronic pelvic pain associated with adenomyosis after insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS), stratified into mild, moderate and severe pain groups and assessed by visual analog scale (VAS) plus transvaginal ultrasound. VAS scores fell from 9.0 ± 0.8 at baseline to 1.3 ± 1.3 at 12 months, with significant improvement at each follow-up interval, and no factors universally predicting pain relief were identified — improvement was not tied to changes in menstrual pattern or to adverse events. The authors conclude LNG-IUS is a cost-effective, reversible, long-term option that may reduce the need for surgery, particularly in mild-to-moderate pain, while noting that hormonal treatments for adenomyosis remain symptomatic rather than cytoreductive. This paper is centrally about adenomyosis — evaluating LNG-IUS as uterus-sparing conservative therapy for adenomyosis-associated chronic pelvic pain.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: To observe the effects of levonorgestrel-releasing intrauterine system (LNG-IUS) in treatment of chronic pelvic pain associated with adenomyosis (AM) and in prevention of its recurrence. METHODS: A prospective continuing study including 180 patients with chronic pelvic pain associated with AM who received insertion of LNG-IUS who were divided into three groups depending on the pain severity. The visual analog scale (VAS) was used for pain assessment before and during the treatment and transvaginal ultrasonic measurement of the uterine size, while various side effects, were observed and recorded. RESULTS: After placement of LNG-IUS, scores of pain and ratio of severe pelvic pain decreased significantly compared with baselines (p < 0.01), the scores of VAS were 9.0 ± 0.8, 6.5 ± 2.8, 4.3 ± 1.8, 3.3 ± 2.2, 2.2 ± 2.1, 2.2 ± 1.8, 1.4 ± 1.6 and 1.3 ± 1.3 at 0, 3, 6 and 12 months, respectively. During 12 months after placement of LNG-IUS, scores of pain had improved significantly compared with preceding period (p 0.005). CONCLUSION: The obtained results allowed to confirm the possibility of using LNG-IUS in the treatment of pelvic pain syndrome associated with AM, particularly with mild and moderately severe pelvic pain syndrome. This is a cost effective, reversible and long-term treatment for women with pelvic pain associated with AM, which reduces the need for surgical interventions.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

mesh:D017699adenomyosischronic_pelvic_pain

MeSH descriptors

Adenomyosis Chronic Pain Contraceptive Agents, Female Intrauterine Devices, Medicated Levonorgestrel Outcome Assessment, Health Care Pelvic Pain Adenomyosis Adult Chronic Pain Chronic Pain Contraceptive Agents, Female Contraceptive Agents, Female Female Humans Levonorgestrel Levonorgestrel Middle Aged Pelvic Pain Pelvic Pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (8)

Cited by (16)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:20:49.724109+00:00
License: CC0 · commercial use OK